This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Halfon, P. Articles by Ouzan, D. Search for Related Content PubMed PubMed Citation Articles by Halfon, P. Articles by Ouzan, D.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, July 2006, p. 2507-2511, Vol. 44, No. 7
0095-1137/06/$08.00+0     doi:10.1128/JCM.00163-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Real-Time PCR Assays for Hepatitis C Virus (HCV) RNA Quantitation Are Adequate for Clinical Management of Patients with Chronic HCV Infection

Alphabio Laboratory, Marseille, France,¹ Department of Hepatology and Gastroenterology, Saint-Joseph Hospital, Marseille, France,² Department of Biostatistics and Epidemiology, CDL Pharma, Marseille, France,³ Department of Hepatology and Gastroenterology, Arnault Tzanck Institute, Saint Laurent du Var, France⁴

Received 25 January 2006/ Returned for modification 3 April 2006/ Accepted 13 April 2006

Because of the use of viral kinetics during polyethylene glycol (PEG)-interferon-ribavirin therapy and the development of specific new anti-hepatitis C virus (anti-HCV) drugs, assessment of the efficacy of anti-HCV drugs needs to be based not on end-point PCR assays but on real-time PCR. The aim of this study was to determine if the two available commercial real-time PCR assays, the Abbott RealTime HCV assay and the Roche Cobas TaqMan HCV assay, can become the standard for HCV RNA quantification. We investigated the prognostic relevance of HCV RNA viral loads at baseline, week 4, and week 12 to a rapid and early virological response to antiviral therapy by using the two assays. Of 59 naïve patients chronically infected by HCV (41 infected with genotype 1) who were treated with ribavirin plus PEG-interferon alfa-2b for 48 weeks, 24 patients (41%) showed a sustained virological response (SVR). With the two assays, viral loads were highly correlated, irrespective of genotype (R² = 0.94 for all cases). No difference in diagnostic value was found between the Abbott and Roche assays at week 4, with respective negative predictive values (NPVs) of 84% and 78% and positive predictive values (PPVs) of 62% and 56% (not significant), and at week 12, the respective NPVs were 91% and 90% and PPVs were 44% and 46% (not significant). At week 12, 83% (20/24) and 96% (23/24) of patients with SVR tested negative for HCV RNA by the Abbott and Roche assays, respectively (the difference is not significant). In conclusion, the high sensitivities and large dynamic ranges of the Abbott and Roche assays show that a single real-time quantitative PCR assay is fully adequate for clinical and therapeutic management of HCV.

This article has been cited by other articles:

• Halfon, P., Bourliere, M., Ouzan, D., Sene, D., Saadoun, D., Khiri, H., Penaranda, G., Martineau, A., Oules, V., Cacoub, P. (2008). Occult Hepatitis C Virus Infection Revisited with Ultrasensitive Real-Time PCR Assay. J. Clin. Microbiol. 46: 2106-2108 [Abstract] [Full Text]  
• Colucci, G., Ferguson, J., Harkleroad, C., Lee, S., Romo, D., Soviero, S., Thompson, J., Velez, M., Wang, A., Miyahara, Y., Young, S., Sarrazin, C. (2007). Improved COBAS TaqMan Hepatitis C Virus Test (Version 2.0) for Use with the High Pure System: Enhanced Genotype Inclusivity and Performance Characteristics in a Multisite Study. J. Clin. Microbiol. 45: 3595-3600 [Abstract] [Full Text]  
• Laperche, S., Bouchardeau, F., Thibault, V., Pozzetto, B., Vallet, S., Rosenberg, A. R., Roque-Afonso, A.-M., Gassin, M., Stoll-Keller, F., Trimoulet, P., Gault, E., Chanzy, B., Mercier, B., Branger, M., Pawlotsky, J.-M., Henquell, C., Lunel, F., Gaudy-Graffin, C., Alain, S., Chaix, M.-L., Duverlie, G., Izopet, J., Lefrere, J.-J. (2007). Multicenter Trials Need To Use the Same Assay for Hepatitis C Virus Viral Load Determination. J. Clin. Microbiol. 45: 3788-3790 [Abstract] [Full Text]